NCELHealthcare · BiotechnologyThe 1 Wall Street analysts covering NewCelX Ltd. hold a median 12-month price target of $23 — +572.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores NewCelX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (88): Smaller than most of the companies we track.
Volatility (3): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own NewCelX Ltd. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on NCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +572.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | Laidlaw & Co. | Initiates | Buy | $23 |
| 13 July 2026 | Laidlaw & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 41% of US stocks
Cheaper than 81% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 11% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NCEL appears on the weeks it earns a place.
NewcelX announced a $1.4 million equity financing priced at a 20% premium, following a successful FDA pre-IND meeting for its lead Type 1 diabetes program.
Why it matters — The pricing at a premium signals strong investor confidence and the financing will support the advancement of NewcelX's lead Type 1 diabetes program.
The 1 Wall Street analysts covering NewCelX Ltd. have a median 12-month price target of $23, with estimates ranging from $23 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering NewCelX Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NewCelX Ltd. 17 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, NewCelX Ltd. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +572.5% from the last close, and Ticker Nerd's factor model ranks NewCelX Ltd. 17 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NewCelX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $23 over the next 12 months.
NewCelX Ltd. returned -81.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for rare and complex central nervous system (CNS) disorders.
The most recent item we track (GlobeNewsWire, 31 July 2026): "NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing". NewcelX announced a $1.4 million equity financing priced at a 20% premium, following a successful FDA pre-IND meeting for its lead Type 1 diabetes program.
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for rare and complex central nervous system (CNS) disorders. Headquartered in Zurich, Switzerland, the company leverages advanced scientific platforms, including its proprietary dual orexin receptor agonist (DOXA) technology, to target neurobehavioral and neurocognitive challenges such as narcolepsy, ADHD, and other sleep-related conditions. NLS Pharmaceutics is committed to delivering safer, more effective treatments that address significant unmet medical needs in the global CNS therapeutics market. Its pipeline includes lead candidates like Mazindol ER, designed to improve symptoms in patients with narcolepsy and ADHD, as well as other investigational assets targeting neurodegenerative diseases. The company’s research is supported by a network of world-class partners and scientists, emphasizing rigorous clinical development and robust intellectual property. In October 2025, NLS Pharmaceutics completed a strategic merger with Kadimastem Ltd., forming NewcelX Ltd., which consolidates expertise in both drug development and cell therapy to broaden its impact across neurodegenerative diseases and diabetes. This evolution positions the company at the forefront of next-generation CNS therapies, combining cutting-edge science with a patient-centric approach to drive meaningful advances in brain health.
CEO Mr. Ronen Twito CPA · 9 employees · Switzerland · https://newcelx.com